Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | HTT | P42858 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | HTR7 | P34969 | 5/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30277537 | 1.00 | LMNA (0.69) | LMNAHTTMAPTTSHRMAPK1 | |
| SCHEMBL2149024 | 0.95 | LMNA (0.68) | LMNAHTTMAPTTSHRMAPK1 | |
| SCHEMBL8134198 | 0.94 | LMNA (0.66) | LMNAHTTMAPTTSHRMAPK1 | |
| SCHEMBL961132 | 0.90 | LMNA (0.64) | LMNAHTTMAPTTSHRMAPK1 | |
| SCHEMBL30947438 | 0.90 | LMNA (0.78) | LMNAHTTMAPTTSHRMAPK1 | |
| SCHEMBL6902600 | 0.83 | RAB9A (0.72) | LMNAHTTMAPTTSHRMAPK1 | |
| SCHEMBL891454 | 0.83 | LMNA (0.69) | LMNAHTTMAPTTSHRMAPK1 | |
| SCHEMBL28297946 | 0.83 | LMNA (0.69) | LMNAHTTMAPTTSHRMAPK1 | |
| SCHEMBL318943 | 0.83 | LMNA (0.69) | LMNAHTTMAPTTSHRMAPK1 | |
| SCHEMBL6397082 | 0.83 | LMNA (0.69) | LMNAHTTMAPTTSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115754066-B | Method for detecting related substances in domperidone tablet | 佛山手心制药有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119044362-A | Analysis method of domperidone intermediate DP-2 related substances | 华东医药（西安）博华制药有限公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-119000976-A | Detection method of norfloxacin capsule related substances, test solution and application | 佛山手心制药有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-115754066-A | Method for detecting related substances in domperidone tablets | 佛山手心制药有限公司 | 2023-03-07 | — | — | CN | disclosed |
| US-9765053-B2 | Methods of treatment using selective 5-HT2A inverse agonists | ACADIA PHARMACEUTICALS INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20170165273-A9 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | ANDERSSON CARL-MAGNUS A (DK) | 2017-06-15 | — | — | US | disclosed |
| EP-3138841-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| EP-1787984-B1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARM INC (US) | 2016-10-19 | — | — | EP | disclosed |
| US-20160237036-A1 | AZACYCLIC COMPOUNDS | ACADIA PHARM INC (US) | 2016-08-18 | — | — | US | disclosed |
| CN-105439960-A | Synthesis method of domperidone drug intermediate 1-(3-chloropropyl)-benzimidazolyl-2-one | CHENGDU CARDIFF SCIENCE AND TECH CO LTD | 2016-03-30 | — | — | CN | disclosed |
| EP-0037713-A1 | Novel 1,3-dihydro-1-((1-piperidinyl)alkyl)-2H-benzimidazol-2-one derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-10-14 | — | — | EP | disclosed |
| US-4254127-A | ANTIEMETIC, NEUROLIPTIC AND ANTICONGESTIVE AGENT | JANSSEN PHARMACEUTICA, N.V. (BE) | 1981-03-03 | — | — | US | disclosed |
| US-4250176-A | BENZIMIDAZOLE-2-ONE, BENZOTHIAZOL-2-ONE, OR BENZOXAZOL-2-ONE SUBSTITUTIONS, ANTIANAPHALACTIC AGENTS, ANTIHISTAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-02-10 | — | — | US | disclosed |
| US-4200641-A | ANTIANAPHYLACTIC AGENTS, ANTIHISTAMINES | JANSSEN PHARMACEUTICA, N.V. (BE) | 1980-04-29 | — | — | US | disclosed |
| US-4175129-A | Antiemetic 1-(benzoxazolylalkyl)-piperidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-11-20 | — | — | US | disclosed |
| US-4160836-A | Antiemetic 1-(benzothiazolylalkyl)piperidine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-07-10 | — | — | US | disclosed |
| US-4126688-A | ANTIEMETIC 1-(BENZOTRIAZOLYL-ALKYL)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1978-11-21 | — | — | US | disclosed |
| US-4126687-A | ANTIEMETIC, 1-(BENZIMIDAZOLYL-ALKYL)-PIPERIDINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 1978-11-21 | — | — | US | disclosed |
| US-4110333-A | ANTIEMETIC INTERMEDIATES | JANSSEN PHARMACEUTICA N.V. (BE) | 1978-08-29 | — | — | US | disclosed |
| US-4066772-A | ANTIEMETICS | JANSSEN PHARMACEUTICA N.V. (BE) | 1978-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170165273-A9 | METHODS OF TREATMENT USING SELECTIVE 5-HT2A INVERSE AGONISTS | HTR2A, HTR5A, HTR3B | LMNA 1770/4885HTT 304/4885MAPT 3060/4885 |
| US-20160237036-A1 | AZACYCLIC COMPOUNDS | HTR6, TPMT, HNMT | LMNA 3064/4885HTT 541/4885MAPT 2692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.